Unknown

Dataset Information

0

Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma.


ABSTRACT: Flavopiridol (FVP; Alvocidib), a CDKs inhibitor, is currently undergoing clinical trials for treatment of leukemia and other blood cancers. Our studies demonstrated that FVP also inhibited p38 kinases activities with IC50 (μM) for p38α: 1.34; p38 β: 1.82; p38γ: 0.65, and p38δ: 0.45. FVP showed potent cytotoxicity in cutaneous T-cell lymphoma (CTCL) Hut78 cells, with IC50 <100 nM. NMR analysis revealed that FVP bound to p38γ in the ATP binding pocket, causing allosteric perturbation from sites surrounding the ATP binding pocket. Kinomic profiling with the PamGene platform in both cell-based and cell-free analysis further revealed dosage of FVP significantly affects downstream pathways in treated CTCL cells, which suggested a need for development of synergistic drugs with FVP to prevent its clinically adverse effects. It led us discover niclosamide as a synergistic drug of FVP for our future in vivo study.

SUBMITTER: Zhang XH 

PROVIDER: S-EPMC8248901 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5955096 | biostudies-literature
| S-EPMC6214075 | biostudies-literature
| S-EPMC3495819 | biostudies-literature
| S-EPMC521075 | biostudies-literature
| S-EPMC3934299 | biostudies-literature
| S-EPMC4127485 | biostudies-literature
| S-EPMC4097832 | biostudies-literature
| S-EPMC5511568 | biostudies-literature
2014-08-03 | GSE60027 | GEO
| S-EPMC3203811 | biostudies-other